EMCDDA news

Resilience, agility and innovation are among the recurring themes in the latest EMCDDA General Report of Activities, released today. The annual publication — presenting key achievements and governance — relates how the EMCDDA executed its work programme in 2020, a special year marking its 25 years of monitoring, but also the arrival of COVID-19. 15.06.2021 

Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way in which we live. Countries in Europe, and around the world, have had to introduce unprecedented measures to protect public health. All aspects of the drug phenomenon in Europe — including production, trafficking, distribution and use — have also been affected by the pandemic. The European Drug Report 2021 this year provides the latest overview of these developments. 09.06.2021 

Today, the EU drugs agency (EMCDDA) publishes its European Drug Report 2021: Trends and Developments, the latest annual review of the drug situation in Europe (1). Based on data from 29 countries (EU 27, Turkey and Norway), the report offers new insights into the health and security implications of a complex and evolving drugs problem and of a drug market resilient to COVID-19 disruption. 09.06.2021  European Drug Report 2021: Highlights

New benzodiazepines, which are not controlled by international drug laws, come under the spotlight today in a new report released by the EU drugs agency (EMCDDA) (1). Often marketed as ‘designer benzodiazepines’, these substances are sold as ‘legal’ replacements for controlled benzodiazepines and are becoming increasingly available in Europe. 09.06.2021  New benzodiazepines under the spotlight